CLGN Valuation

Collplant Biotechnologies Ltd

Add to Watchlist

Advanced Chart

2.600

-0.04(-1.515%)1D

Overview
Forecast
Valuation
Earnings

CLGN Relative Valuation

CLGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CLGN is overvalued; if below, it's undervalued.

Historical Valuation

Collplant Biotechnologies Ltd (CLGN) is now in the Fair zone, suggesting that its current forward PS ratio of 1.89 is considered Fairly compared with the five-year average of 10.17. The fair price of Collplant Biotechnologies Ltd (CLGN) is between 2.20 to 4.62 according to relative valuation methord.

Relative Value

Fair Zone

2.20-4.62

Current Price：2.58

Fair

13.54

Trailing

Forward

0.00

EV/EBITDA

Collplant Biotechnologies Ltd. (CLGN) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-6.81

EV/EBIT

Collplant Biotechnologies Ltd. (CLGN) has a current EV/EBIT of -6.81. The 5-year average EV/EBIT is 3.73. The thresholds are as follows: Strongly Undervalued below -43.54, Undervalued between -43.54 and -19.91, Fairly Valued between 27.36 and -19.91, Overvalued between 27.36 and 50.99, and Strongly Overvalued above 50.99. The current Forward EV/EBIT of -6.81 falls within the Historic Trend Line -Fairly Valued range.

1.89

Collplant Biotechnologies Ltd. (CLGN) has a current PS of 1.89. The 5-year average PS is 55.67. The thresholds are as follows: Strongly Undervalued below -170.65, Undervalued between -170.65 and -57.49, Fairly Valued between 168.83 and -57.49, Overvalued between 168.83 and 281.99, and Strongly Overvalued above 281.99. The current Forward PS of 1.89 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Collplant Biotechnologies Ltd. (CLGN) has a current P/OCF of 0.00. The 5-year average P/OCF is -1.21. The thresholds are as follows: Strongly Undervalued below -5.34, Undervalued between -5.34 and -3.28, Fairly Valued between 0.85 and -3.28, Overvalued between 0.85 and 2.91, and Strongly Overvalued above 2.91. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Collplant Biotechnologies Ltd. (CLGN) has a current P/FCF of 0.00. The 5-year average P/FCF is -1.17. The thresholds are as follows: Strongly Undervalued below -5.14, Undervalued between -5.14 and -3.15, Fairly Valued between 0.82 and -3.15, Overvalued between 0.82 and 2.81, and Strongly Overvalued above 2.81. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Collplant Biotechnologies Ltd (CLGN) has a current Price-to-Book (P/B) ratio of 2.68. Compared to its 3-year average P/B ratio of 2.39 , the current P/B ratio is approximately 12.12% higher. Relative to its 5-year average P/B ratio of 3.99, the current P/B ratio is about -32.71% higher. Collplant Biotechnologies Ltd (CLGN) has a Forward Free Cash Flow (FCF) yield of approximately -32.21%. Compared to its 3-year average FCF yield of -19.90%, the current FCF yield is approximately 61.81% lower. Relative to its 5-year average FCF yield of -13.43% , the current FCF yield is about 139.86% lower.

2.68

P/B

Median3y

2.39

Median5y

3.99

-32.21

FCF Yield

Median3y

-19.90

Median5y

-13.43

Competitors Valuation Multiple

The average P/S ratio for CLGN's competitors is 0.59, providing a benchmark for relative valuation. Collplant Biotechnologies Ltd Corp (CLGN) exhibits a P/S ratio of 1.89, which is 218.84% above the industry average. Given its robust revenue growth of -28.11%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CLGN.O

Collplant Biotechnologies Ltd

Vivos Therapeutics Inc

X T L Biopharmaceuticals Ltd

0.03

10.49M

AIFF.O

Firefly Neuroscience Inc

Precision Optics Corporation Inc

Vicarious Surgical Inc

Loss

34.46M

Performance Decomposition

Market capitalization of CLGN decreased by 46.83% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -1.69K to -1.87K.

The secondary factor is the Revenue Growth, contributed -28.11%to the performance.

Overall, the performance of CLGN in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-28.11%

249.00K → 179.00K

Revenue Growth

10.59%

-1.69K → -1.87K

Margin Expansion

-29.31%

-3.32 → -2.35

P/E Change

-46.83%